Last reviewed · How we verify
ABT-652
ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | ABT-652 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 2 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, which suppresses the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce inflammation in conditions driven by excessive immune activation, particularly in respiratory and inflammatory diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
- A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain (PHASE2)
- A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee (PHASE2)
- A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee (PHASE2)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-652 CI brief — competitive landscape report
- ABT-652 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI